Key facts
- NeedleCalm’s last known valuation is $1.0M (Feb 2025).
- It has raised $1.4M; the latest was Later Stage VC ($300K) in Feb 2025.
- Notable investors include Microsoft for Startups, Artesian, Investment NSW, Medtech Actuator.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for NeedleCalm
- ·The full record, as it builds
Funding rounds
No funding rounds for NeedleCalm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeedleCalm
Operator of a medical company intended to reduce the pain and anxiety associated with needle-related procedures. The company uses technology that reduces the discomfort associated with needles helps increase compliance with guidelines and improves patient and staff satisfaction, enabling clinicians to make needle-related healthcare services better in terms of time and resources.
- Sector
- Healthcare
- HQ
- Sydney, Australia
- Founded
- 2016
- Employees
- 3
- Website
- needlecalm.com.au/
- Ownership
- Privately Held (backing)
NeedleCalm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeedleCalm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeedleCalm in its N-PORT filings yet. We sweep new filings monthly.